An Open-label Randomized Phase II Study of Panitumumab Plus Oral Capecitabine and Infusional Oxaliplatin (XELOX) or XELOX Alone for Second-line Treatment of Patients With Metastatic Colorectal Cancer (VOXEL-Study).

Trial Profile

An Open-label Randomized Phase II Study of Panitumumab Plus Oral Capecitabine and Infusional Oxaliplatin (XELOX) or XELOX Alone for Second-line Treatment of Patients With Metastatic Colorectal Cancer (VOXEL-Study).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2013

At a glance

  • Drugs Panitumumab (Primary) ; Capecitabine; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms VOXEL
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 07 Sep 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top